Neurocrine Biosciences (NBIX) Change in Taxes (2024 - 2026)

Neurocrine Biosciences (NBIX) has reported Change in Taxes for 3 consecutive years, with -$59.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Taxes fell 15000.0% year-over-year to -$59.6 million; the trailing twelve-month figure through Jun 2026 stood at $25.6 million (changed N/A YoY), and the FY2025 full-year result was -$18.8 million, down 137.38% from the prior year.
• Change in Taxes declined to -$59.6 million in Q2 2026 per NBIX's latest filing, from $119.8 million in the prior quarter.
• Across five years, Change in Taxes topped out at $119.8 million in Q1 2026 and bottomed at -$70.1 million in Q3 2025.
• Historically, Change in Taxes has averaged $13.8 million across 3 years, with a median of $15.4 million in 2025.
• The widest YoY moves for Change in Taxes: up 677.92% in 2026, down 15000.0% in 2026.
• Over 3 years, Change in Taxes stood at $55.1 million in 2024, then tumbled by 35.57% to $35.5 million in 2025, then plunged by 267.89% to -$59.6 million in 2026.
• According to Business Quant data, Change in Taxes over the past three periods registered -$59.6 million, $119.8 million, and $35.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.